The APEX trial is a randomized, placebo-controlled study that evaluated the long-term effects of zumilokibart. Results indicated that the drug not only maintained but also deepened responses across all lesional and itch endpoints over the 52-week period. Notably, the trial reported a 77% reduction in itch scores for the 3-month dosing group and a 67% reduction for the 6-month dosing group, further highlighting the drug's potential as a leading treatment option in the AD market.
Apogee plans to initiate Phase 3 trials of zumilokibart in the second half of 2026, with a potential commercial launch targeted for 2029. The company believes that zumilokibart could capture a significant share of the projected $50 billion AD market, especially given its differentiated dosing regimen compared to existing therapies, which often require more frequent administration.
The safety profile of zumilokibart was consistent with other agents in its class, with a low rate of treatment-emergent adverse events (TEAEs). The most common TEAEs included noninfective conjunctivitis and upper respiratory tract infections, which were manageable and did not lead to significant discontinuation rates.
Overall, the results from the APEX trial position zumilokibart as a potentially best-in-class therapy for AD, with the ability to provide durable disease control with fewer injections per year, addressing a critical unmet need in the treatment landscape for atopic dermatitis.
